Cardiovascular Systems
Cardiovascular Systems, Inc. (CSI) is a medical technology company dedicated to developing and commercializing innovative solutions for treating peripheral and coronary vascular diseases. The company focuses on addressing complex conditions such as peripheral arterial disease (PAD) and coronary artery disease (CAD), particularly those related to calcium build-up. CSI's primary offerings include catheter-based platforms, specifically its orbital atherectomy systems, which are designed to remove plaque from leg arteries and are applicable in both peripheral and coronary settings. The Diamondback 360 Peripheral and Stealth 360 systems represent key products in their portfolio. The majority of CSI's revenue is generated from sales of these peripheral products, primarily within the United States. Through a commitment to clinical rigor and continuous innovation, CSI aims to improve patient outcomes by providing safe and effective medical devices.
Developer of an online doctor consultation platform designed to improve the outcomes of patients suffering from peripheral artery disease. The company's platform empowers podiatrists, skilled nursing facilities, home health agencies, primary care physicians to capture patient information, wound images and measurements, enabling users to take good care of themselves consulting with doctors online without going to the clinic.
Leviticus Cardio Ltd is a medical technology company based in Petach Tikva, Israel, founded in 2008. The company specializes in developing a wireless coplanar energy transfer system designed to address the power needs of patients with congestive heart failure. Its primary product, the Fully Implanted Ventricular Assist Device (FIVAD), is a wireless heart pump system that eliminates the need for an external power pack connected by a drive line. This innovation aims to reduce the risk of infections associated with traditional VAD systems, which pose significant challenges for patients relying on these devices. Leviticus Cardio targets a critical patient population in the United States, where approximately 30,000 to 60,000 individuals with severe heart failure are candidates for either heart transplantation or mechanical circulatory support. The company's solutions are designed to be robust, efficient, and straightforward to implant, ultimately enhancing the quality of life for heart failure patients.
Replidyne is a specialty pharmaceutical company focused on developing and commercializing innovative anti-infective products. The company is building its development pipeline based on both its proprietary DNA replication technology and in-licensing efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.